IFNG and Alzheimer disease: Subsequently, the DEGs of lesional vs. non-lesional core signature genes were calculated for the high (n = 1061) and low (n = 879) IFNG AD groups and were compared with dupilumab response genes (n = 685) to characterize the gene response pattern of both AD groups with regard to dupilumab therapy (Figure 6C).